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Um método rápido por cromatografia líquida foi desenvolvido para a determinação simultânea 
de omeprazol (OMZ), 5-hidroxiomeprazol (5-HOMZ) e omeprazol sulfona (OMZ SUL) em meio de 
cultura líquido, para aplicação em estudos de biotransformação empregando fungos fitopatogênicos 
e endofíticos. A separação foi realizada empregando uma coluna monolítica Chromolith Fast 
gradient RP 18 com a fase móvel constituída por ácido trifluoroacético (TFA) 0,15% (v/v) em 
água (solvente A) e TFA 0,15% (v/v) em acetonitrila (solvente B). Foi empregado um gradiente 
linear de 5 a 90% de B em 1 minuto, vazão de 1,0 mL min-1, temperatura de 30 ºC e detecção em 
220 nm. A extração líquido-líquido foi empregada na preparação das amostras, com recuperações 
na faixa de 62,3-76,6% para todos os analitos. O método foi linear na faixa de 0,2-10,0 µg mL-1 
(r ≥ 0,995). Os valores de precisão e exatidão intra- e inter-dias (coeficiente de variação e erro 
relativo) foram inferiores a 15% para todos os analitos. O método validado foi utilizado para avaliar 
a biotransformação do OMZ em seus principais metabólitos humanos pelos fungos selecionados. 
Em geral, os fungos fitopatogênicos foram mais eficientes para biotransformar o OMZ. A reação 
de sulfonação foi mais prevalente em todos os fungos estudados.
A fast liquid chromatography method was developed and validated for the simultaneous 
determination of omeprazole (OMZ), 5-hydroxyomeprazole (5-HOMZ) and omeprazole sulphone 
(OMZ SUL) in liquid culture medium for application in biotransformation studies employing 
phytopathogenic and endophytic fungi. The separation was achieved using a monolithic 
Chromolith Fast gradient RP 18 endcapped column, using a mobile phase consisting of 0.15% (v/v) 
trifluoroacetid acid (TFA) in water (solvent A) and 0.15% (v/v) TFA in acetonitrile (solvent B), 
under linear gradient of 5 to 90% of B in 1 min, flow rate of 1.0 mL min-1, temperature at 
30 ºC and detection at 220 nm. Sample preparation was performed by liquid-liquid extraction, 
with recoveries in the range of 62.3 to 76.6% for all analytes. The method was linear in the range 
of 0.2 to 10.0 µg mL-1 (r ≥ 0.995). The values for intra- and inter-day precision (% coefficient 
of variation) and accuracy (% relative error) were < 15% for all analytes. The validated method 
was used to evaluate OMZ biotransformation to their mammalian metabolites by selected fungi. 
In general, the phytopathogenic fungi studied were more efficient to biotransform OMZ. The 
sulfonation reaction was more prevalent for all studied fungi.
Keywords: fast liquid chromatography, monolithic column, omeprazole, 5-hydroxyomeprazole, 
omeprazole sulphone, biotransformation
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Introduction
Omeprazole (OMZ) is a proton pump inhibitor 
used in the treatment of dyspepsia, peptic ulcer disease, 
gastroesophageal reflux disease and Zollinger-Ellison 
syndrome. Its mechanism of action is selective by 
an inhibition of the hydrogen-potassium adenosine 
triphosphatase enzyme (H+/K+ ATPase) of the parietal 
cells, leading to a reduction of the gastric acid secretion.1-3 
The main metabolites of OMZ observed in human plasma 
are 5-hydroxyomeprazole (5-HOMZ) and omeprazole 
sulphone (OMZ SUL) (Figure 1). It is well established that 
CYP2C19 is the major enzyme involved in the formation 
of 5-HOMZ whereas CYP3A4 is mainly involved in the 
production of OMZ SUL.4
Several analytical methods for the determination of 
OMZ alone or with its metabolites in biological samples, 
bulk material or pharmaceutical formulations, have been 
reported in the literature. Older methods were extensively 
reviewed by Bosch et al.5 For the analysis of OMZ and 
its metabolites in biological matrices, HPLC has been the 
technique most employed.5-13 Although these methods are 
quite suitable for the analysis of OMZ and its metabolites 
in biological matrices, all of them are characterized by 
relatively long analysis time. Recently, we studied the high-
speed analysis of OMZ in pharmaceutical formulations 
using a monolithic column.14 Based on the good results 
obtained, we decided to use this column to develop a 
method for the simultaneous determination of OMZ, 
5-HOMZ and OMZ SUL in liquid culture medium to study 
the biotransformation of OMZ by fungi.
The evaluation of the efficacy and safety of a drug 
requires large amounts of metabolites to be used in the 
development of analytical methods, in pharmacokinetic, 
pharmacodynamic and toxicologic studies and others. 
These metabolites could be obtained by using synthetic 
routes which posses disadvantages such as relatively 
complicated synthesis, multi-step process, large amount of 
halogen-containing wastes and the use of some very toxic 
reactants. An alternative procedure is the use of microbial 
models15-17 as some microorganisms can metabolize 
drugs in a similar manner to mammals. Fungi have been 
extensively used for biotransformation studies since they 
provide an efficient and environmentally friendly means for 
achieving large-scale metabolite production of a range of 
drugs.18-20 They can generate the same metabolites produced 
by humans and other mammals as well as metabolites 
unique to their genus.
In this study, OMZ was selected as a model drug 
to evaluate the effectiveness of phytopathogenic and 
endophytic fungi to perform sulfonation and hydroxylation 
reactions. The term endophytic fungi have been employed 
to describe those fungi that can be detected at a particular 
moment within apparently healthy plant host tissue. 
Endophytes invade the tissue of living plants causing 
unapparent and asymptomatic infections.21,22 Endophytic 
fungi have been employed in biotransformation studies 
of different drugs.23-29 Phytopathogenic fungi can cause 
disease by colonizing parts of animals and plants internally 
or externally. Phytopathogenic fungi may also exhibit 
long latency periods, that is, symptom-free occupation of 
host tissue.30 Some phytopathogenic fungi have been also 
employed in biotransformation process.31,32
Experimental
Chemicals and reagents
OMZ and OMZ SUL were kindly supplied by 
AstraZeneca (Mölndal, Sweden). 5-HOMZ was obtained 
Figure 1. Chemical structures of omeprazole (OMZ), 5-hydroxyomeprazole (5-HOMZ), omeprazole sulphone (OMZ SUL) and bupropion (BUP, I.S.).
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from Toronto Research Chemicals Inc. (North York, ON, 
Canada). Bupropion (internal standard, IS) was kindly 
supplied by Glaxo Smith Kline (Rio de Janeiro, RJ, Brazil). 
All reagents used in the biotransformation reactions were 
analytical grade in the highest purity available. All aqueous 
solutions were prepared with water distilled and purified 
using a Millipore Milli-Q Plus system (Bedford, MA, USA). 
HPLC-grade methanol and acetonitrile were obtained from 
Merck (Darmstadt, Germany). Trifluoroacetic acid, ethyl 
acetate and ethanol (p.a. grade) were purchased from 
PRS (Barcelona, Spain). tert-Butyl ethyl ether (p.a.) was 
obtained from Sigma Aldrich (Dorset, UK).
Instrumentation and analytical conditions
Experiments were performed on a LaChromUltra 
Hitachi High Technologies chromatographic system 
(Pleasanton, CA, USA) consisting of a double L-2160 U 
pump, an L-2455 U Diode Array Detector, an organizer, 
an L-2200 U auto sampler, and an L-2300 column oven. 
The EZChrom Elite software (Agilent Technologies, 
Pleasanton, CA, USA) was used to control the LC system 
and for data acquisition. Separation was performed on a 
Chromolith Fast gradient RP 18 endcapped column (Merck, 
50 × 2.0 mm). The separation was accomplished with a 
mobile phase consisting of 0.15% (v/v) trifluoroacetic 
acid (TFA) in water (solvent A) and 0.15% (v/v) TFA in 
acetonitrile (ACN) (solvent B), using a linear gradient of 
5 to 90% of B in 1 min. Diode array detection was from 
190 to 600 nm (UV at 220 nm for data analysis). All 
chromatographic procedures were conducted at 30 °C. A 
flow rate of 1.0 mL min-1 was used. The injection volume 
was 5 mL for standards and samples.
Preparation of standards
Stock standard solutions of OMZ, 5-HOMZ and OMZ 
SUL were prepared by dissolution of the drugs in methanol 
to obtain a concentration of 2000 µg mL-1. From these stock 
solutions, working standards were prepared by dilutions 
to obtain the concentrations of 16, 20, 40, 80, 240, 480 
and 800 mg mL-1. The concentration of internal standard 
bupropion (BUP) was 100 mg mL-1. The stock solutions and 
the working standards were stored at –20 ºC in well-closed 
and light resistant containers.
Sample preparation
The extraction of 1 mL aliquots of the liquid culture 
medium spiked with 25 µL of bupropion (IS, 100 mg mL-1) 
was performed with 4 mL of a mixture of ethyl acetate: 
t-butyl methyl ether (9:1, v/v), after alkalinization with 
100 µL of 2 mol L-1 NaOH solution. Drugs were extracted 
into a vortex shaker for 3 min. After centrifugation at 
1800×g for 3 min, the organic phase (3 mL) was separated 
and the solvent was evaporated under nitrogen. The residue 
was dissolved in 400 µL of mobile phase and placed in the 
automatic injector for injection of 5 µL.
Method validation
The selectivity of the method was evaluated by 
analyzing sterile medium and fungal mycelium under 
the conditions previously established to verify possible 
interferents of reagents and secondary metabolites of each 
studied fungi.
The recovery study was performed extracting 1 mL 
liquid culture medium spiked with standard solutions of 
OMZ, 5-HOMZ and OMZ SUL to obtain the concentrations 
of 1.0, 3.0 and 6.0 µg mL-1 (n = 3). Another set of samples 
was prepared extracting 1 mL aliquots of liquid culture 
medium and then spiking the extract with the same amount 
of OMZ, 5-HOMZ and OMZ SUL. The recovery was 
determined by comparing the areas obtained before and 
after extraction and was expressed as percentage of the 
amount extracted.
Calibration curves were prepared by analyzing aliquots 
of 1 mL of liquid culture medium spiked with OMZ and 
its metabolites to achieve the final concentrations of 0.20, 
0.25, 0.50, 1.0, 3.0, 6.0 and 10.0 mg mL-1. Bupropion (IS) 
was added to all samples. The tests were performed in 
triplicates for each concentration.
The limits of quantification (LOQ), defined as the 
lowest concentration that could be determined with 
accuracy and precision below 20%,33 were determined by 
analyzing samples of 1 mL of liquid culture medium (n = 6) 
spiked with 5-HOMZ, OMZ and OMZ SUL to obtain a 
concentration of 0.20 mg mL-1.
Within-day precision and accuracy were achieved by six 
replicates analysis (n = 6) of liquid culture medium samples 
spiked with standard solutions of the drug and metabolites 
at low, medium and high concentration levels (1.0, 3.0 and 
6.0 mg mL-1). Between-day precision and accuracy were 
conducted during routine operation of the system over 
a period of three consecutive working days. The overall 
precision of the method was expressed as percentage of 
coefficient of variation (CV, %), while the accuracy was 
expressed as percentage of relative error (E, %).
The stability test of 5-HOMZ, OMZ and OMZ SUL 
was evaluated by studying the influence of freeze (–20 ºC) 
and thaw (22 ± 2 ºC) cycles, short-term room temperature 
(8 h on the auto sampler) and 48 h stored at –20 ºC. Six 
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replicates (n = 6) of spiked liquid culture medium at the 
low (1.0 mg mL-1) and high concentration (6.0 mg mL-1) 
were prepared to perform the stability test. The peak areas 
obtained from the stability tests were compared to the peak 
areas obtained with freshly prepared samples. One-way 
ANOVA test was applied, with the level of significance 
set at p ≤ 0.05.
Endophytic and pathogenic fungi isolation and maintenance
The phytopatogenic fungi selected were Botrytis 
cinerea 2100 (BC), Colletotrichum acutatum 348489 
(CA), Colletotrichum gloeosporioides 20122 (CG) and 
Eutypa lata (EL). The phytopatogenic fungi employed in 
this work were obtained from the “Colección Española de 
Cultivos Tipo” (CECT). The selected strains of endophytic 
fungi were Glomerella cingulata (VA1) and Guignardia 
mangiferae (VA15) isolated from V. arenaria, Penicillium 
crustosum (VR4), Chaetomium globosum (VR10) and 
Aspergillus fumigatus (VR12) isolated from V. robusta. The 
strains have been deposited in the Academic Laboratory of 
Chemistry of Microorganisms, Faculty of Pharmaceutical 
Sciences of Ribeirão Preto (University de São Paulo, 
Ribeirão Preto, Brazil). The fungi have been maintained as 
conidial stock suspensions or agar plugs in 80% glycerol 
at –70 oC.
Biotransformation study of OMZ employing endophytic 
and phytopathogenic fungi
Fungi were grown at 25 ºC for 7 days in 9.0 cm 
diameter Petri dishes containing potato dextrose agar. 
Three uniform discs of 0.9 cm diameter of each fungus 
studied were transferred aseptically to 50 mL Falcon tubes 
containing 10 mL of pre-fermentative medium (10.0 g 
malt extract, 10.0 g dextrose, 5.0 g triptone and 3.0 g yeast 
extract and distilled water to 1 L. The pH was adjusted to 
6.2 ± 0.2 with a solution of 0.5 mol L-1 HCl) for the growth 
of the microorganisms. After five days, the mycelium 
was completely transferred to 500 mL Erlenmeyer flask 
containing 200 mL of modified buffered Czapek Dox 
medium (2.0 g glucose, 0.2 g yeast, 0.4 g NaNO3, 0.1 g 
MgSO4•7H2O, 0.002 g FeSO4•7H2O, 13.9 g K2HPO4, 10.9 g 
KH2PO4, and distilled water to 100 mL, pH adjusted to 7.0). 
Solutions of OMZ (2 mg) in ethanol were added to each of 
studied culture. The cultures were incubated with orbital 
shaking (120 rpm) at 25 oC for 24 h in the darkness. Aliquots 
were filtered through a Millipore membrane filter (0.45 mm, 
Millipore, Bedford, MA, USA) and then 1 mL of filtrate 
was submitted to extraction procedure and analyzed by the 
method described in this paper. Control tubes consisted of 
culture broth without OMZ and fungi, sterile medium with 
OMZ without fungi and fungal mycelium of each studied 
endophytic and phytopathogenic fungi.
Results and Discussions
Method development and validation
The demand for new analytical technologies able to 
promote fast or ultra fast separation using short columns 
packed with small particles (i.e. sub-2 µm)34-39 resistant 
to high pressure or high temperature mobile phase40-45 
has grown in the last years. In addition, a possible tool 
to convert a standard LC method into a fast LC method 
is the use of monolithic silica columns. Due to the high 
permeability of monolithic columns46-49 provided by the 
bimodal pore structure, high flow rates can be used with 
acceptable backpressure.50,51
The analysis of OMZ in enteric coated pellets has 
already been studied by our group.14 Some modifications 
on the method were performed to achieve the simultaneous 
separation of OMZ, 5-HOMZ and OMZ SUL. Although the 
method has used a fast gradient employing a flow rate of 
1 mL min-1, no re-equilibrium was necessary to perform the 
next analysis. The best conditions were achieved providing 
satisfactory resolution for all analytes (Rs > 2.5) in only 
1 min. The optimized chromatographic conditions are 
described on Figure 2 that also shows typical chromatogram 
of OMZ, 5-HOMZ, OMZ SUL and BUP (IS). Under these 
conditions, 5-HOMZ eluted around 0.70 min, OMZ with 
0.74 min, OMZ SUL with 0.79 min. Some compounds were 
evaluated as internal standard and among them bupropion 
(BUP) presented better results (0.91 min).
Figure 3 shows the chromatograms obtained for 
the analysis of blank liquid culture medium of the 
phytopathogenic fungi (Figure 3a) and endophytic fungi 
(Figure 3b) after 24 h of incubation. The evaluation of 
method selectivity showed that only the fungus Penicillium 
crustosum (VR4) presented secondary metabolites co-
eluting with the analytes. A secondary metabolite presented 
a peak at the same retention time of BUP. Therefore, this 
microorganism was removed from the study.
Some solvents or mixture of solvents at different 
compositions were evaluated to extract 5-HOMZ, OMZ, 
and OMZ SUL from liquid culture medium employing 
liquid-liquid extraction (LLE) and the selected one was 
ethyl acetate: tert-butyl methyl ether (9: 1, v/v). Recoveries 
of 5-HOMZ, OMZ, and OMZ SUL were approximately 
65, 75 and 67%, respectively. The percentages of CV for 
all analytes were lower than 15%. Results are summarized 
in Table 1.
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Response ratio of peak areas between the corresponding 
compound and the internal standard versus theoretical 
concentration was fitted by a least-square linear regression. 
The calibration curves were linear over the concentration 
range of 0.2-10 mg mL-1. The correlation coefficients 
for all analytes were (r) ≥ 0.99 (Table 2). The limits of 
quantification of the validated method are also presented 
in Table 2. The coefficients of variation and relative errors 
were lower than 15%.
The results for within-day and between-day precision 
and accuracy at concentration levels of 1.0, 3.0 and 6.0 µg 
mL-1 for 5-HOMZ, OMZ, and OMZ SUL are summarized 
in Table 3. These results show that the method is precise 
and accurate within the desired range.
To perform the stability test, spiked liquid culture 
medium were prepared in six replicates (n = 6). The 
samples at the low (1.0 µg mL-1) and high concentration 
(6.0 µg mL-1) were analyzed freshly, after 8 h on the auto 
sampler, after freeze/thaw cycles, or after 48 h frozen at 
–20 oC. Stability data are summarized in Table 4. As can be 
seen from the values, there were no statistically significant 
loss since all p-values were > 0.05 (one-way ANOVA, NS).
OMZ stability studies reported in the literature have 
revealed that it is acid labile and sensitive to light and 
heat, suggesting the possible formation of degradation 
products.53 Therefore, the biotransformation reaction of 
OMZ was conducted in darkness and in buffered medium 
(pH 7.0).
The stability of OMZ under the biotransformation 
conditions was evaluated by the analysis of a control tube 
consisting of sterile medium with OMZ. No degradation 
of OMZ could be observed up to 24 h incubation. Studies 
with time over 24 h showed that there was significant 
degradation of the substrate OMZ.
Figure 2. Typical chromatogram showing the (A) Blank of liquid culture medium and (B) the separation of 5-HOMZ, OMZ, OMZ SUL and BUP. 
Chromatographic conditions: Chromolith Fast gradient RP 18 endcapped column (Merck, 50 × 2.0 mm id); linear gradient of 0.15% (v/v) trifluoroacetid 
acid (TFA) in water (solvent A) and 0.15% (v/v) TFA acetonitrile (ACN) (solvent B), 5 to 90% of B in 1 min; column temperature of 30 °C; flow rate 
of 1.0 mL min-1 and DAD detection from 190 to 600 nm (UV at 220 nm for data analysis). The injection volume was 5 mL for standards and samples.
Table 1. Extraction yield data for 5-hydroxyomeprazole, omeprazole and omeprazole sulphone in Czapek Dox medium
Drug 5-Hydroxyomeprazole Omeprazole Omeprazole Sulfone
1 µg mL-1
Recovery (mean, %)a 62.3 75.3 67.9
CV (%)b 5.1 2.7 4.0
3 µg mL-1
Recovery (mean, %)a 62.5 73.9 65.9
CV (%)b 6.0 3.5 5.9
6 µg mL-1
Recovery (mean, %)a 66.3 76.6 66.1
CV (%)b 1.8 5.4 5.2
aRecovery with three replicates (n = 3), expressed in percentage (%); bCV, expressed as coefficient of variation in percentage (%).
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Figure 3. A) Chromatograms referring to the analysis of liquid culture medium of the phytopatogenic fungi: Botrytis cinerea (BC), Colletotrichum acutatum 
(CA), Colletotrichum gloeosporioides (CG) and Eutypa lata (EL); B) Chromatograms referring to the analysis of liquid culture medium of the endophytic 
fungi: Glomerella cingulata (VA1, 1: unknown secondary metabolite), Guignardia mangiferae (VA15, 2: unknown secondary metabolite), Penicillium 
crustosum (VR4, 3: unknown secondary metabolite), Chaetomium globosum (VR10, 4, 5 and 6: unknown secondary metabolites) and Aspergillus fumigatus 
(VR12). The conditions are the same as in Figure 2.
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Table 2. Linearity and limit of quantification of the method for the analysis of 5-hydroxyomeprazole, omeprazole and omeprazole sulphone in Czapek 
Dox medium
Drug 5-Hydroxyomeprazole Omeprazole Omeprazole Sulfone
Linear equation
Slope 0.4852 0.5660 0.5281
Intercept 0.1113 0.1439 0.1551
Correlation coefficient (r) 0.9974 0.9959 0.9959
LOQ
Nominal Concentration (µg mL-1) 0.20 0.20 0.20
Analyzed Concentration (µg mL-1) 0.20 0.20 0.20
CV (%)a 10.3 7.3 3.2
E (%)b 0.3 -0.1 -0.1
aCV, expressed as coefficient of variation in percentage (%); bE, expressed as relative error in percentage (%).
Table 3. Precision and accuracy of the method for the analysis of 5-hydroxyomeprazole, omeprazole and omeprazole sulphone in Czapek Dox medium
Drug 5-Hydroxyomeprazole Omeprazole Omeprazole Sulfone
Nominal concentration (µg mL-1) 1.00 3.00 6.00 1.00 3.00 6.00 1.00 3.00 6.00
Intra-day (n = 6)
Analyzed concentration (µg mL-1) 0.94 2.70 5.46 0.92 2.88 5.29 0.88 3.05 5.50
Precision (CV, %)a 5.3 7.9 4.2 4.0 12.8 9.9 3.9 9.0 6.1
Accuracy (E, %)b -6.4 -10.1 -9.0 -8.1 -3.9 -11.9 -12.5 1.8 -8.3
Inter-day (n = 3)
Analyzed concentration (µg mL-1) 0.89 2.73 5.37 0.92 2.77 5.21 0.87 2.96 5.30
Precision (CV, %)a 6.5 7.7 6.4 5.5 14.4 7.1 9.4 6.3 7.8
Accuracy (E, %)b -10.6 -9.0 -10.5 -7.8 -7.6 -13.2 -12.7 -1.3 -11.7
aCV, expressed as coefficient of variation in percentage (%); bE, expressed as relative error in percentage (%); cn = number of determinations: 6 for intra-
day assay and 3 for inter-day assay.
Table 4. Stability test of 5-hydroxyomeprazole, omeprazole and omeprazole sulphone in Czapek Dox medium
Drug 5-Hydroxyomeprazole Omeprazole Omeprazole Sulfone
p-valueb CV (%)c E (%)d p-valueb CV (%)c E (%)d p-valueb CV (%)c E (%)d
8 h auto sampler (n = 6) a
1 µg mL-1 0.72 5.9 1.3 0.92 5.7 -0.3 0.81 4.1 0.5
6 µg mL-1 0.74 3.8 -0.9 0.81 5.1 0.8 0.67 2.4 1.2
Freeze-thaw cycles (n = 6) a
1 µg mL-1 0.70 4.9 1.3 0.73 1.9 0.9 0.99 5.8 -0.1
6 µg mL-1 0.90 7.3 -0.5 0.99 7.3 -0.1 0.69 5.3 -1.4
48 h freeze(n = 6) a
1 µg mL-1 0.99 8.9 0.1 0.86 7.2 0.7 0.81 6.6 0.7
6 µg mL-1 0.93 7.2 0.3 0.93 4.1 0.2 0.66 3.4 1.3
an = number of determinations; bLevel of significance set at p ≤ 0.05; cCV, expressed as coefficient of variation in percentage (%); dE, expressed as relative 
error in percentage (%).
Application of method in the biotransformation study of 
OMZ by endophytic and phytopathogenic fungi
The biotransformation of OMZ by Cunninghamella 
elegans ATCC 9245 was previously studied.54 These 
authors reported that the predominant pathway involved in 
this biotransformation was the reduction of the sulphoxide 
group to sulfide and the hydroxylation of the molecule’s 
aromatic rings and side chain.
The biotransformation reactions of OMZ that were 
monitored in this work involves the aliphatic hydroxylation 
of the methyl group of the aromatic ring yielding the 
formation of the metabolite 5-HOMZ and the sulfonation 
(in the sulfur atom) resulting the metabolite OMZ SUL. 
Table 5 presents the obtained data.
The fungus Colletotrichum acutatum (CA) 
biotransformed 9.6% of OMZ to OMZ SUL in 24 h of 
incubation. In addition, Botrytis cinerea (BC) was the 
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Figure 4. A) Chromatograms referring to the analysis of biotransformation process employing the phytopatogenic fungi: Botrytis cinerea (BC, 1 and 2: 
unknown biotransformation products), Colletotrichum acutatum (CA, 1 and 3: unknown biotransformation products), Colletotrichum gloeosporioides (CG, 
1 and 3: unknown biotransformation products) and Eutypa lata (EL, 1 and 3: unknown biotransformation products); B) Chromatograms referring to the 
analysis of biotransformation process the endophytic fungi: Glomerella cingulata (VA1, 1: unknown biotransformation product and 2: unknown secondary 
metabolite), Guignardia mangiferae (VA15, 1: unknown biotransformation product and 3: unknown secondary metabolite), Chaetomium globosum (VR10, 
1: unknown biotransformation product, 4, 5 and 6: unknown secondary metabolites) and Aspergillus fumigatus (VR12, 1: unknown biotransformation 
product). The conditions are the same as in Figure 2.
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Table 5. Biotransformation of omeprazole to 5-hydroxyomeprazole and/or omeprazole sulphone
Fungi Initial concentration (µg mL-1) Obtained concentration (µg mL-1) after 24 h incubation
Omeprazole Omeprazolea 5-Hydroxyomeprazole Omeprazole Sulphone
Phytopathogenic fungib
Botrytis cinerea (BC) 9.34 (100 %) 6.23 (66.8 %) 0.20 (2.1 %) 0.68 (7.3 %)
Colletotrichum acutatum (CA) 9.52 (100 %) 5.05 (54.7 %) < LOQ 0.91 (9.6 %)
Colletotrichum gloeosporioides (CG) 9.33 (100 %) 7.59 (81.3 %) NDc 0.62 (6.6 %)
Eutypa lata (EL) 9.21 (100 %) 7.05 (74.1 %) NDc 0.53 (5.8 %)
Endophytic fungib
Glomerella cingulata (VA1) 9.27 (100 %) 6.59 (71.1 %) NDc < LOQ
Guignardia mangiferae (VA15) 9.65 (100 %) 6.49 (67.3 %) NDc < LOQ
Chaetomium globosum (VR10) 9.56 (100 %) 5.00 (52.4 %) NDc < LOQ
Aspergillus fumigatus (VR12) 9.14 (100 %) 7.61 (83.3 %) < LOQ 0.40 (4.3 %)
aAnalysis in duplicate (n = 2); bThe control flasks did not present formation of the omeprazole metabolites; cND: non-detected.
only fungus that biotransformed OMZ to 5-HOMZ (2.1%). 
Figure 4 shows the chromatograms of all phytopathogenic 
fungi (Figure 4a) and endophytic fungi (Figure 4b) 
studied after 24 h of incubation. The spectra of all target 
peaks were compared with the standard and purity peaks 
were calculated and presented values higher than 0.99. 
As informed before, longer incubation times were not 
evaluated due to OMZ decomposition.
In general, the phytopathogenic fungi studied were 
more efficient to biotransform OMZ, and the four fungi 
studied were able to form the metabolite OMZ SUL. The 
sulfonation reaction was more prevalent for all studied 
fungi. The difference in biotransformation process could 
be attributed to the different enzymes present in the studied 
strains. Therefore, the production of a specific metabolite 
OMZ could be assigned by selecting the appropriate fungus.
Conclusions
The method developed in this study employing fast 
liquid chromatography for the simultaneous resolution of 
OMZ, 5-HOMZ and OMZ SUL was performed in a short 
period of time (< 2.0 min), allowing the analysis of large 
number of samples with low use of organic solvents. The 
method validated presented all parameters in accordance 
with the confidence criteria established in the literature. 
The method was successfully applied to study the 
biotransformation of OMZ by fungi. The phytopathogenic 
fungi studied were more efficient to biotransform OMZ, 
and OMZ SUL was the main metabolite obtained.
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